Background: The extracellular matrix protein tenascin-C has been discovered to be an important regulator of the response to tissue injury and repair in cerebrovascular diseases. This study investigated if tenascin-C is released in response to infections in the central nervous system (CNS).
Methods: Tenascin-C concentration in the cerebrospinal fluid (CSF) was measured in patients, (>18 years) with and without CNS infections, admitted to a department of infectious diseases in Denmark. CSF tenascin-C was measured on the Meso-scale platform.
Results: 174 patients were included of which 140 were diagnosed with a CNS infection and 34 where this was ruled out (control group). Median CSF tenascin-C levels were significantly higher among patients with bacterial meningitis (147 pg/mL), viral meningitis (33 mg/mL), viral encephalitis (39 pg/mL) and Lyme neuroborreliosis (45 pg/mL) when compared to controls (21 pg/mL). Correlations between tenascin-C and CSF markers of inflammation and age were only moderate.
Conclusion: Levels of CSF tenascin-C are higher among patients with bacterial and viral neuroinfections, already on admission, but exhibit only a modest correlation with baseline indices of neuroinflammation. CSF tenascin-C is highest among patients with bacterial meningitis compared to the other CNS infections. Patients with unfavorable outcomes presented with higher median CSF tenascin-C than their counterparts.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jneuroim.2024.578373 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long-term outcomes in antibody-negative autoimmune encephalitis: a retrospective study.
J Neurol
December 2024
Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 1St ST SW, Rochester, MN, 55905, USA.
Background And Objective: Despite constituting one-third of suspected autoimmune encephalitis (AE) patients, antibody-negative cases without typical AE features are understudied. We aim to characterize the clinical phenotypes and long-term outcomes of "possible only" and "probable" AE cases.
Methods: We conducted a retrospective analysis of adult patients evaluated at Mayo Clinic's Autoimmune Neurology Clinic (01/01/2006-12/31/2020), meeting diagnostic criteria for "possible only" or "probable but antibody-negative" AE, with ≥ 1 year of follow-up.
Evaluating the associations between intelligence quotient and multi-tissue proteome from the brain, CSF and plasma.
Brain Commun
June 2024
NHC Key Laboratory of Environment and Endemic Diseases, School of Public Health, Health Science Center, Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, China.
Intelligence quotient is a vital index to evaluate the ability of an individual to think rationally, learn from experience and deal with the environment effectively. However, limited efforts have been paid to explore the potential associations of intelligence quotient traits with the tissue proteins from the brain, CSF and plasma. The information of protein quantitative trait loci was collected from a recently released genome-wide association study conducted on quantification data of proteins from the tissues including the brain, CSF and plasma.
View Article and Find Full Text PDFTenascin-C in patients with central nervous system infections.
J Neuroimmunol
July 2024
Department of Infectious Diseases, Zealand University Hospital, University of Copenhagen, Roskilde, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen Region, Copenhagen, Denmark.
Background: The extracellular matrix protein tenascin-C has been discovered to be an important regulator of the response to tissue injury and repair in cerebrovascular diseases. This study investigated if tenascin-C is released in response to infections in the central nervous system (CNS).
Methods: Tenascin-C concentration in the cerebrospinal fluid (CSF) was measured in patients, (>18 years) with and without CNS infections, admitted to a department of infectious diseases in Denmark.
MOG Antibody-Associated Disease in the Setting of Metastatic Melanoma Complicated by Immune Checkpoint Inhibitor Use.
Neurol Neuroimmunol Neuroinflamm
July 2024
From the Departments of Neurology (S.B.S.-M., H.Z.-F., Y.G., N.T., J.J.C., A.Z., C.F.L., R.M., E.P.F.), Ophthalmology (J.J.C.), Internal Medicine (I.K.), and Oncology (J.J.O., M.S.B.), Mayo Clinic, Rochester, MN; and Neurology (C.F.L.), University of Texas at Austin.
Article Synopsis
- MOGAD is a rare autoimmune disease linked to demyelination, and this case study focuses on a patient who also had metastatic melanoma.
- The patient, a 52-year-old man, showed high levels of MOG-IgG and had significant MRI findings, which indicated inflammation and demyelination, but no MOG presence in the tumor tissue itself.
- Treatment involved several approaches including steroids and immunotherapy for both MOGAD and melanoma, with tocilizumab ultimately leading to a strong and lasting improvement in his condition, highlighting its potential as a dual treatment option.
Immune Checkpoint Inhibitor-Associated Kelch-Like Protein-11 IgG Brainstem Encephalitis.
Neurol Neuroimmunol Neuroinflamm
May 2024
From the Center for Multiple Sclerosis and Autoimmune Neurology (A.A., N.V., Y.G., S.H., A.Z., J.J.C., D.D.), Department of Neurology; Department of Laboratory Medicine and Pathology (N.V., Y.G., A.Z., D.D.); Department of Neurology (N.V.), Mayo Clinic College of Medicine, Rochester, MN; Division of Neurology (M.V.P.), Department of Medicine, Faculty of Medicine, Khon Kaen University, Thailand; and Department of Ophthalmology (J.J.C.), Mayo Clinic College of Medicine, Rochester, MN.
Article Synopsis
- KLHL11-IgG has been linked to rhombencephalitis and seminoma, but its role as a neurologic immune checkpoint inhibitor-related adverse event for esophageal adenocarcinoma had not been previously identified.
- A 61-year-old man with metastatic esophageal adenocarcinoma developed severe neurological symptoms after undergoing treatment that included nivolumab.
- The patient's diagnosis of KLHL11-IgG rhombencephalitis as a novel adverse event was confirmed through various tests, leading to a change in his treatment plan to prevent further neurological decline.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!